Phase III Orbit study

Portnoy Law Firm sues Ultragenyx on behalf of investors over alleged misstatements regarding Phase III Orbit study methodology and efficacy claims for setrusumab.

Ultragenyx Pharmaceutical faces securities fraud lawsuit alleging misrepresentations of setrusumab trial results and inadequate risk disclosures to investors.

Class action lawsuit filed against $UGXY alleging securities fraud over misleading setrusumab trial data and OI patient safety disclosures.

Class action lawsuit filed against $UGXY alleging securities fraud related to setrusumab clinical trial data. Investors from August 2023 to December 2025 eligible.

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.

Ultragenyx faces class action lawsuit alleging false statements about its osteogenesis imperfecta drug's efficacy after Phase III trial failed to meet primary endpoint.